DPP4 and hepatocellular carcinoma: These findings suggest that DPP-4 inhibitors may be associated with preventing the development of chronic HCV infection, and therefore DPP-4 inhibitors may be associated with the primary prevention of HCC in patients without chronic HCV infection.